name,pdb_id,pubmed_id,resolution,uniprot,PFAM,CATH,receptor_chain,receptor_length,peptide_chain,peptide_length,sequence_alignment,stride,percent_exposed_alignment,cluster_number,binding_mode,size_of_binding_mode,core_ecr_alignment,longest_continuous_core,longest_continuous_ecr,corebinding_aa,exosite_aa,surface_aa,interior_aa,corebinding_ss,exosite_ss,surface_ss,interior_ss,unique_id,COREBINDING_aa,COREBINDING_ss,EXOSITE_aa,EXOSITE_ss,bfact,bs_loc_type,full_peptide_sequece,mean_seq_iden_in_bm,mean_seq_iden_not_bm,min_dist_E_C_diff_bm,occupancy,pep_loc_type,title
1K74_D_E_18_1.pdb,1K74,11698662,2.30,P37231,PF00104,1.10.565.10,D,272,E,16,E--------------RHKILHRLLQEGSPS---,T--------------TTHHHHHHHHHCCCC---,3--------------403001100230136---,18,1,19,E--------------EDDCCCCCCCDEEEE---,7,5,D:0;E:0;F:0;I:0;K:0;L:0;P:0;Q:0;T:0;V:0,D:0;E:0;F:0;I:0;K:0;L:0;P:0;Q:0;T:0;V:0,A:2;D:3;E:3;F:2;G:2;H:1;I:1;K:13;L:1;M:3;N:3;P:3;Q:2;S:5;T:3;Y:2,A:14;C:1;D:14;E:14;F:12;G:9;H:5;I:19;K:8;L:35;M:6;N:5;P:7;Q:12;R:8;S:11;T:9;V:12;Y:6,G:0;H:0;T:0,G:0;H:0;T:0,C:12;E:1;G:1;H:19;T:16,C:18;E:12;G:4;H:140;T:33,18_1,D:0;E:2;F:1;I:1;K:2;L:2;P:1;Q:2;T:1;V:2,G:1;H:13;T:0,D:1;E:0;F:0;I:0;K:1;L:0;P:0;Q:0;T:0;V:0,G:0;H:0;T:2,6--------------665555555677888---,ASP_270_D_EXOSITE;GLN_109_D_COREBINDING;GLN_89_D_COREBINDING;GLU_266_D_COREBINDING;GLU_93_D_COREBINDING;ILE_267_D_COREBINDING;LEU_106_D_COREBINDING;LEU_263_D_COREBINDING;LYS_114_D_COREBINDING;LYS_269_D_EXOSITE;LYS_96_D_COREBINDING;PHE_101_D_COREBINDING;PRO_262_D_COREBINDING;THR_92_D_COREBINDING;VAL_110_D_COREBINDING;VAL_88_D_COREBINDING,CPSSHSSLTERHKILHRLLQEGSPS,0.568218954248366,0.205882352941176,1.27728266253011,9--------------999999999999999---,GLU_1_E_E;ARG_2_E_E;HIS_3_E_E;LYS_4_E_E;ILE_5_E_C;LEU_6_E_C;HIS_7_E_C;ARG_8_E_C;LEU_9_E_C;LEU_10_E_C;GLN_11_E_C;GLU_12_E_E;GLY_13_E_E;SER_14_E_E;PRO_15_E_E;SER_16_E_E,"THE 23 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HETERODIMER OF 2 THE HUMAN PPARGAMMA AND RXRALPHA LIGAND BINDING DOMAINS RESPECTIVELY 3 BOUND WITH GW409544 AND 9CIS RETINOIC ACID AND COACTIVATOR 4 PEPTIDES"
1K7L_G_H_18_1.pdb,1K7L,11698662,2.50,Q07869,PF00104,1.10.565.10,G,267,H,13,E--------------RHKILHRLLQEG------,T--------------TTHHHHHHHHCC------,2--------------202001200332------,18,1,19,E--------------EDECCCCCCCde------,7,4,D:0;E:0;F:0;I:0;K:0;L:0;P:0;Q:0;R:0;T:0;V:0,D:0;E:0;F:0;I:0;K:0;L:0;P:0;Q:0;R:0;T:0;V:0,A:4;C:1;D:4;E:3;F:1;G:1;I:1;K:11;L:1;M:1;N:6;P:2;Q:1;S:6;T:2;Y:2,A:18;C:6;D:11;E:12;F:13;G:10;H:8;I:16;K:8;L:29;M:10;N:8;P:6;Q:8;R:8;S:5;T:6;V:17;Y:5,G:0;H:0;T:0,G:0;H:0;T:0,C:7;G:6;H:16;T:18,C:22;E:13;G:5;H:137;T:27,18_1,D:0;E:2;F:1;I:1;K:1;L:3;P:1;Q:1;R:0;T:2;V:1,G:1;H:12;T:0,D:1;E:0;F:0;I:0;K:1;L:0;P:0;Q:0;R:1;T:0;V:0,G:0;H:1;T:2,8--------------887777778888------,ARG_264_G_EXOSITE;ASP_265_G_EXOSITE;GLN_104_G_COREBINDING;GLU_261_G_COREBINDING;GLU_88_G_COREBINDING;ILE_262_G_COREBINDING;LEU_101_G_COREBINDING;LEU_108_G_COREBINDING;LEU_258_G_COREBINDING;LYS_109_G_EXOSITE;LYS_91_G_COREBINDING;PHE_96_G_COREBINDING;PRO_257_G_COREBINDING;THR_84_G_COREBINDING;THR_87_G_COREBINDING;VAL_105_G_COREBINDING,HSSLTERHKILHRLLQEGSPS,0.536214094019014,0.198501872659176,1.90901178623915,9--------------999999999999------,GLU_1_H_E;ARG_2_H_E;HIS_3_H_E;LYS_4_H_E;ILE_5_H_C;LEU_6_H_C;HIS_7_H_C;ARG_8_H_C;LEU_9_H_C;LEU_10_H_C;GLN_11_H_C;GLU_12_H_e;GLY_13_H_e,"THE 25 ANGSTROM RESOLUTION CRYSTAL STRUCTURE OF THE HUMAN 2 PPARALPHA LIGAND BINDING DOMAIN BOUND WITH GW409544 AND A 3 COACTIVATOR PEPTIDE"
1NQ7_A_B_18_1.pdb,1NQ7,12958591,1.50,P45446,PF00104,1.10.565.10,A,244,B,10,----------------HKILHRLLQE-------,----------------CHHHHHHHHC-------,----------------1310120023-------,18,1,19,----------------deCCCCCCCd-------,7,2,E:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,E:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,A:3;D:4;E:4;G:1;H:1;K:5;L:3;M:2;N:2;P:1;Q:6;R:1;S:3;T:2;W:2;Y:1,A:15;C:7;D:5;E:15;F:12;G:6;H:7;I:17;K:10;L:25;M:3;N:9;P:5;Q:11;R:6;S:8;T:11;V:12;W:1;Y:6,H:0,H:0,C:4;G:2;H:26;T:9,B:1;C:15;E:10;G:5;H:143;T:17,18_1,E:1;I:1;K:2;L:3;M:1;P:1;Q:2;V:1,H:12,E:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,H:0,----------------6655554677-------,GLN_81_A_COREBINDING;GLN_84_A_COREBINDING;GLU_241_A_COREBINDING;ILE_85_A_COREBINDING;LEU_238_A_COREBINDING;LEU_242_A_COREBINDING;LEU_88_A_COREBINDING;LYS_71_A_COREBINDING;LYS_89_A_COREBINDING;MET_77_A_COREBINDING;PRO_237_A_COREBINDING;VAL_67_A_COREBINDING,HKILHRLLQE,0.311345151700086,0.487903225806452,2.02495308587631,----------------9999999999-------,HIS_1_B_e;LYS_2_B_e;ILE_3_B_C;LEU_4_B_C;HIS_5_B_C;ARG_6_B_C;LEU_7_B_C;LEU_8_B_C;GLN_9_B_C;GLU_10_B_e,"CHARACTERIZATION OF LIGANDS FOR THE ORPHAN NUCLEAR RECEPTOR 2 RORBETA"
1RDT_D_E_18_1.pdb,1RDT,15056000,2.40,P37231,PF00104,1.10.565.10,D,253,E,7,-----------------KQLSELL---------,-----------------HHHHHHC---------,-----------------4101301---------,18,1,19,-----------------dCCCCCC---------,6,1,E:0;F:0;I:0;K:0;L:0;Q:0;T:0;V:0,E:0;F:0;I:0;K:0;L:0;Q:0;T:0;V:0,A:2;D:5;E:7;F:2;G:2;K:11;L:2;M:1;N:2;P:3;Q:1;S:4;T:4;Y:2,A:15;C:1;D:12;E:8;F:11;G:8;H:5;I:18;K:8;L:33;M:7;N:6;P:6;Q:11;R:8;S:11;T:7;V:12;Y:6,G:0;H:0,G:0;H:0,C:12;E:1;G:2;H:20;T:13,C:17;E:12;G:7;H:139;T:18,18_1,E:2;F:1;I:1;K:1;L:2;Q:2;T:1;V:2,G:1;H:11,E:0;F:0;I:0;K:0;L:0;Q:0;T:0;V:0,G:0;H:0,-----------------8888888---------,GLN_71_D_COREBINDING;GLN_91_D_COREBINDING;GLU_248_D_COREBINDING;GLU_75_D_COREBINDING;ILE_249_D_COREBINDING;LEU_245_D_COREBINDING;LEU_95_D_COREBINDING;LYS_78_D_COREBINDING;PHE_83_D_COREBINDING;THR_74_D_COREBINDING;VAL_70_D_COREBINDING;VAL_92_D_COREBINDING,NLVPDAASKHKQLSELLRGGSGS,0.57735568137611,0.225296442687747,2.29818711161646,-----------------9999999---------,LYS_1_E_e;GLN_2_E_C;LEU_3_E_C;SER_4_E_C;GLU_5_E_C;LEU_6_E_C;LEU_7_E_C,"CRYSTAL STRUCTURE OF A NEW REXINOID BOUND TO THE RXRALPHA 2 LIGAND BINDING DOAMIN IN THE RXRALPHAPPARGAMMA HETERODIMER"
2NPA_A_B_18_1.pdb,2NPA,17157019,2.30,Q07869,PF00104,1.10.565.10,A,269,B,15,-----------LT-ERHKILHRLLQEG------,-----------TT-TTTHHHHHHHHHC------,-----------31-2203100200232------,18,1,19,-----------EE-EEEDCCCCCCCde------,7,6,D:0;E:0;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;R:0;T:0;V:0,D:0;E:0;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;R:0;T:0;V:0,A:8;D:3;E:4;F:1;G:1;K:9;L:1;M:1;N:5;P:2;S:4;T:2,A:16;C:7;D:12;E:12;F:13;G:10;H:8;I:17;K:9;L:29;M:10;N:8;P:6;Q:9;R:8;S:7;T:7;V:16;Y:6,C:0;H:0;T:0,C:0;H:0;T:0,C:8;H:20;T:13,C:16;E:13;G:3;H:147;T:31,18_1,D:0;E:2;F:1;I:0;K:2;L:3;N:0;P:1;Q:1;R:0;T:2;V:2,C:0;H:13;T:1,D:1;E:0;F:0;I:1;K:0;L:0;N:1;P:0;Q:0;R:1;T:0;V:0,C:2;H:2;T:0,-----------78-7645545545579------,ARG_267_A_EXOSITE;ASN_105_A_EXOSITE;ASP_268_A_EXOSITE;GLN_107_A_COREBINDING;GLU_264_A_COREBINDING;GLU_91_A_COREBINDING;ILE_265_A_EXOSITE;LEU_104_A_COREBINDING;LEU_111_A_COREBINDING;LEU_261_A_COREBINDING;LYS_112_A_COREBINDING;LYS_94_A_COREBINDING;PHE_99_A_COREBINDING;PRO_260_A_COREBINDING;THR_87_A_COREBINDING;THR_90_A_COREBINDING;VAL_108_A_COREBINDING;VAL_86_A_COREBINDING,LTERHKILHRLLQEG,0.532256843487315,0.193308550185874,1.01995392052779,-----------99-9999999999999------,LEU_1_B_E;THR_2_B_E;GLU_3_B_E;ARG_4_B_E;HIS_5_B_E;LYS_6_B_E;ILE_7_B_C;LEU_8_B_C;HIS_9_B_C;ARG_10_B_C;LEU_11_B_C;LEU_12_B_C;GLN_13_B_C;GLU_14_B_e;GLY_15_B_e,"THE CRYSTAL STRUCTURE OF THE HUMAN PPARAPLPHA LIGAND 2 BINDING DOMAIN IN COMPLEX WITH A AHYDROXYIMINO 3 PHENYLPROPANOIC ACID"
2P54_A_B_18_1.pdb,2P54,17243659,1.79,Q07869,PF00104,1.10.565.10,A,267,B,12,---------A-----RHKILHRLLQE-------,---------T-----TTHHHHHHHHC-------,---------4-----10300020023-------,18,1,19,---------E-----EEDCCCCCCCd-------,7,4,D:0;E:0;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;R:0;T:0;V:0,D:0;E:0;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;R:0;T:0;V:0,A:4;D:4;E:3;F:1;G:2;H:1;I:1;K:11;L:1;M:1;N:5;P:2;R:1;S:3;T:2;V:1;Y:1,A:18;C:7;D:11;E:12;F:13;G:9;H:7;I:16;K:8;L:29;M:10;N:8;P:6;Q:9;R:7;S:8;T:7;V:15;Y:6,G:0;H:0;T:0,G:0;H:0;T:0,C:5;G:5;H:18;T:16,C:20;E:13;G:9;H:138;T:26,18_1,D:0;E:2;F:1;I:1;K:1;L:3;N:1;P:1;Q:1;R:0;T:1;V:2,G:1;H:13;T:0,D:1;E:0;F:0;I:0;K:1;L:0;N:0;P:0;Q:0;R:1;T:0;V:0,G:0;H:1;T:2,---------9-----98766776689-------,ARG_264_A_EXOSITE;ASN_102_A_COREBINDING;ASP_265_A_EXOSITE;GLN_104_A_COREBINDING;GLU_261_A_COREBINDING;GLU_88_A_COREBINDING;ILE_262_A_COREBINDING;LEU_101_A_COREBINDING;LEU_108_A_COREBINDING;LEU_258_A_COREBINDING;LYS_109_A_EXOSITE;LYS_91_A_COREBINDING;PHE_96_A_COREBINDING;PRO_257_A_COREBINDING;THR_87_A_COREBINDING;VAL_105_A_COREBINDING;VAL_83_A_COREBINDING,ARHKILHRLLQE,0.53538180105189,0.194756554307116,1.71973311882978,---------9-----99999999999-------,ALA_1_B_E;ARG_2_B_E;HIS_3_B_E;LYS_4_B_E;ILE_5_B_C;LEU_6_B_C;HIS_7_B_C;ARG_8_B_C;LEU_9_B_C;LEU_10_B_C;GLN_11_B_C;GLU_12_B_e,"A CRYSTAL STRUCTURE OF PPAR ALPHA BOUND WITH SRC1 PEPTIDE 2 AND GW735"
3ET3_A_P_18_1.pdb,3ET3,19116277,1.95,P37231,PF00104,1.10.565.10,A,260,P,16,--------H-SSLTERHKILHRLLQ--------,--------C-CCCGGGCHHHHHHHC--------,--------5-110022030012003--------,18,1,19,--------E-EEEEEEDDCCCCCCC--------,7,9,D:0;E:0;F:0;G:0;I:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,D:0;E:0;F:0;G:0;I:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,A:3;D:4;E:5;F:1;G:1;K:14;L:1;M:3;N:2;P:2;Q:2;S:4;T:3;Y:2,A:13;C:1;D:13;E:11;F:12;G:9;H:5;I:19;K:5;L:33;M:7;N:5;P:6;Q:10;R:8;S:11;T:7;V:12;Y:6,G:0;H:0;T:0,G:0;H:0;T:0,C:12;G:3;H:19;T:13,C:15;E:13;G:7;H:138;T:20,18_1,D:0;E:2;F:1;G:0;I:1;K:1;L:3;N:0;P:1;Q:2;T:1;V:2,G:1;H:13;T:0,D:1;E:0;F:0;G:1;I:0;K:2;L:0;N:1;P:0;Q:0;T:1;V:0,G:0;H:4;T:2,--------8-655455454445447--------,ASN_96_A_EXOSITE;ASP_97_A_EXOSITE;GLN_78_A_COREBINDING;GLN_98_A_COREBINDING;GLU_255_A_COREBINDING;GLU_82_A_COREBINDING;GLY_183_A_EXOSITE;ILE_256_A_COREBINDING;LEU_102_A_COREBINDING;LEU_252_A_COREBINDING;LEU_95_A_COREBINDING;LYS_103_A_EXOSITE;LYS_258_A_EXOSITE;LYS_85_A_COREBINDING;PHE_90_A_COREBINDING;PRO_251_A_COREBINDING;THR_100_A_EXOSITE;THR_81_A_COREBINDING;VAL_77_A_COREBINDING;VAL_99_A_COREBINDING,HSSLTERHKILHRLLQ,0.580910557918061,0.215384615384615,2.20231105886521,--------9-999999999999999--------,HIS_1_P_E;SER_2_P_E;SER_3_P_E;LEU_4_P_E;THR_5_P_E;GLU_6_P_E;ARG_7_P_E;HIS_8_P_E;LYS_9_P_E;ILE_10_P_C;LEU_11_P_C;HIS_12_P_C;ARG_13_P_C;LEU_14_P_C;LEU_15_P_C;GLN_16_P_C,"STRUCTURE OF PPARGAMMA WITH 35METHOXY14METHOXY 2 BENZENESULFONYL1HINDOL3YLPROPIONIC ACID"
3FEI_A_Z_18_1.pdb,3FEI,19326383,2.40,Q07869,PF00104,1.10.565.10,A,246,Z,8,-------H---------QLLRYLL---------,-------C---------HHHHHHC---------,-------1---------3101310---------,18,1,19,-------e---------dCCCCCC---------,6,2,E:0;H:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,E:0;H:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,A:4;C:1;D:4;E:4;F:1;G:2;H:1;I:1;K:9;L:1;M:3;N:2;P:3;R:3;S:4;T:1;V:2;Y:2,A:15;C:6;D:12;E:12;F:14;G:7;H:6;I:16;K:7;L:27;M:8;N:7;P:4;Q:8;R:6;S:6;T:6;V:12;Y:5,C:0;H:0,C:0;H:0,C:9;G:4;H:22;T:13,C:14;E:13;G:5;H:131;T:21,18_1,E:1;H:1;K:2;L:3;N:1;P:1;Q:1;T:2;V:2,C:1;H:13,E:0;H:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,C:0;H:0,-------6---------6655555---------,ASN_83_A_COREBINDING;GLN_85_A_COREBINDING;GLU_242_A_COREBINDING;HIS_237_A_COREBINDING;LEU_239_A_COREBINDING;LEU_82_A_COREBINDING;LEU_89_A_COREBINDING;LYS_72_A_COREBINDING;LYS_90_A_COREBINDING;PRO_238_A_COREBINDING;THR_65_A_COREBINDING;THR_68_A_COREBINDING;VAL_64_A_COREBINDING;VAL_86_A_COREBINDING,KDHQLLRYLLDKD,0.532959180836844,0.213709677419355,1.81087520276799,-------9---------9999999---------,HIS_1_Z_e;GLN_2_Z_e;LEU_3_Z_C;LEU_4_Z_C;ARG_5_Z_C;TYR_6_Z_C;LEU_7_Z_C;LEU_8_Z_C,"DESIGN AND BIOLOGICAL EVALUATION OF NOVEL BALANCED DUAL 2 PPARAG AGONISTS"
3G9E_A_B_18_1.pdb,3G9E,19349176,2.30,P37231,PF00104,1.10.565.10,A,258,B,10,------H-----------KLVQLLTT----T--,------H-----------HHHHHHHC----C--,------3-----------10120021----5--,18,1,19,------d-----------CCCCCCCd----d--,7,2,E:0;F:0;I:0;K:0;L:0;Q:0;T:0;V:0,E:0;F:0;I:0;K:0;L:0;Q:0;T:0;V:0,A:2;D:6;E:6;F:1;G:2;K:14;L:1;M:2;N:2;P:3;Q:1;R:2;S:5;T:3;Y:2,A:14;C:1;D:12;E:10;F:12;G:9;H:5;I:18;K:6;L:33;M:7;N:6;P:6;Q:11;R:6;S:10;T:8;V:12;Y:6,G:0;H:0,G:0;H:0,C:9;G:3;H:22;T:18,C:12;E:13;G:2;H:145;T:20,18_1,E:2;F:1;I:1;K:2;L:3;Q:2;T:1;V:2,G:1;H:13,E:0;F:0;I:0;K:0;L:0;Q:0;T:0;V:0,G:0;H:0,------6-----------54454445----5--,GLN_76_A_COREBINDING;GLN_96_A_COREBINDING;GLU_253_A_COREBINDING;GLU_80_A_COREBINDING;ILE_254_A_COREBINDING;LEU_100_A_COREBINDING;LEU_250_A_COREBINDING;LEU_93_A_COREBINDING;LYS_101_A_COREBINDING;LYS_83_A_COREBINDING;PHE_88_A_COREBINDING;THR_79_A_COREBINDING;VAL_75_A_COREBINDING;VAL_97_A_COREBINDING,QTSHKLVQLLTTT,0.582067151418834,0.217054263565891,2.11970611170511,------9-----------99999999----9--,HIS_1_B_e;LYS_2_B_C;LEU_3_B_C;VAL_4_B_C;GLN_5_B_C;LEU_6_B_C;LEU_7_B_C;THR_8_B_C;THR_9_B_e;THR_10_B_e,"ALEGLITAAR A NEW POTENT AND BALANCED DUAL PPARAG AGONIST 2 FOR THE TREATMENT OF TYPE II DIABETES"
3KMR_A_C_18_1.pdb,3KMR,20543827,1.80,P10276,PF00104,1.10.565.10,A,234,C,10,------H----------KILHRLLQE-------,------C----------HHHHHHHHC-------,------2----------310220033-------,18,1,19,------d----------eCCCCCCCd-------,7,2,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,E:0;F:0;I:0;K:1;L:0;M:0;P:0;Q:0;V:0,C:1;D:4;E:9;G:1;H:1;K:2;M:3;N:1;P:6;Q:5;R:4;S:3;T:1;Y:1,A:14;C:5;D:11;E:7;F:8;G:9;H:2;I:13;K:10;L:31;M:6;N:4;P:7;Q:6;R:9;S:8;T:18;V:8;W:1;Y:2,G:0;H:0,G:0;H:1,B:1;C:6;G:4;H:17;T:14,B:1;C:19;E:8;G:7;H:122;T:22,18_1,E:1;F:1;I:3;K:1;L:2;M:1;P:1;Q:1;V:1,G:1;H:11,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,G:0;H:0,------6----------654555578-------,GLN_76_A_COREBINDING;GLU_231_A_COREBINDING;ILE_56_A_COREBINDING;ILE_73_A_COREBINDING;ILE_77_A_COREBINDING;LEU_228_A_COREBINDING;LEU_80_A_COREBINDING;LYS_63_A_COREBINDING;LYS_81_A_exosite;MET_232_A_COREBINDING;PHE_68_A_COREBINDING;PRO_227_A_COREBINDING;VAL_59_A_COREBINDING,RHKILHRLLQEGS,0.237689479094467,0.266129032258065,1.33779146356971,------9----------999999999-------,HIS_1_C_e;LYS_2_C_e;ILE_3_C_C;LEU_4_C_C;HIS_5_C_C;ARG_6_C_C;LEU_7_C_C;LEU_8_C_C;GLN_9_C_C;GLU_10_C_e,"CRYSTAL STRUCTURE OF RARALPHA LIGAND BINDING DOMAIN IN COMPLEX WITH AN 2 AGONIST LIGAND AM580 AND A COACTIVATOR FRAGMENT"
3L0L_B_E_18_2.pdb,3L0L,20203100,1.74,P51449,PF00104,1.10.565.10,B,248,E,10,KILHRLLQDS,CHHHHHHHCC,3101310224,18,2,1,CCCCCCCCCC,10,0,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,A:3;C:1;D:1;E:5;H:5;I:1;K:4;L:1;P:3;Q:3;R:6;S:5;T:1;Y:2,A:15;C:7;D:4;E:17;F:12;G:9;H:8;I:9;K:6;L:30;M:5;N:6;P:4;Q:10;R:11;S:13;T:6;V:14;W:2;Y:7,G:0;H:0,G:0;H:0,C:3;G:4;H:25;T:9,B:1;C:22;E:9;G:14;H:125;T:24,18_2,E:1;F:1;I:1;K:2;L:2;M:1;P:1;Q:2;V:1,G:2;H:10,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,G:0;H:0,8778889999,GLN_87_B_COREBINDING;GLN_90_B_COREBINDING;GLU_245_B_COREBINDING;ILE_91_B_COREBINDING;LEU_242_B_COREBINDING;LEU_94_B_COREBINDING;LYS_77_B_COREBINDING;LYS_95_B_COREBINDING;MET_83_B_COREBINDING;PHE_82_B_COREBINDING;PRO_241_B_COREBINDING;VAL_73_B_COREBINDING,EKHKILHRLLQDS,-1,0.406259780296112,,9999999999,LYS_1_E_C;ILE_2_E_C;LEU_3_E_C;HIS_4_E_C;ARG_5_E_C;LEU_6_E_C;LEU_7_E_C;GLN_8_E_C;ASP_9_E_C;SER_10_E_C,"CRYSTAL STRUCTURE OF ORPHAN NUCLEAR RECEPTOR RORGAMMA IN COMPLEX WITH 2 NATURAL LIGAND"
3QT0_A_C_18_1.pdb,3QT0,21986665,2.50,P37231,PF00104,1.10.565.10,A,267,C,12,----E----------RHKILHRLLQE-------,----T----------TTHHHHHHHTT-------,----2----------40310120024-------,18,1,19,----E----------EDDCCCCCCCe-------,7,4,E:0;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,E:0;F:0;I:0;K:1;L:0;N:0;P:0;Q:0;T:0;V:0,A:2;D:5;E:6;F:1;G:2;K:11;L:3;M:2;N:2;P:2;Q:4;R:1;S:3;T:2;Y:2,A:14;C:1;D:12;E:12;F:13;G:9;H:6;I:20;K:9;L:32;M:7;N:5;P:7;Q:10;R:7;S:13;T:8;V:12;Y:6,G:0;H:0;T:0,G:0;H:1;T:0,C:7;E:1;G:2;H:21;T:17,C:15;E:12;G:3;H:139;T:34,18_1,E:1;F:1;I:1;K:0;L:3;N:0;P:1;Q:2;T:1;V:2,G:1;H:11;T:0,E:0;F:0;I:0;K:2;L:0;N:1;P:0;Q:0;T:0;V:0,G:0;H:2;T:1,----6----------65554555566-------,ASN_103_A_EXOSITE;GLN_105_A_COREBINDING;GLN_85_A_COREBINDING;GLU_262_A_COREBINDING;ILE_263_A_COREBINDING;LEU_102_A_COREBINDING;LEU_109_A_COREBINDING;LEU_259_A_COREBINDING;LYS_110_A_EXOSITE;LYS_265_A_EXOSITE;LYS_92_A_exosite;PHE_97_A_COREBINDING;PRO_258_A_COREBINDING;THR_88_A_COREBINDING;VAL_106_A_COREBINDING;VAL_84_A_COREBINDING,ERHKILHRLLQEGSPS,0.572201863392771,0.209737827715356,2.11423319432838,----9----------99999999999-------,GLU_1_C_E;ARG_2_C_E;HIS_3_C_E;LYS_4_C_E;ILE_5_C_C;LEU_6_C_C;HIS_7_C_C;ARG_8_C_C;LEU_9_C_C;LEU_10_C_C;GLN_11_C_C;GLU_12_C_e,"REVEALING A STEROID RECEPTOR LIGAND AS A UNIQUE PPARGAMMA AGONIST"
3SP6_A_B_18_1.pdb,3SP6,21775429,2.21,Q07869,PF00104,1.10.565.10,A,270,B,11,---L--S-----------LLQKLLL-A---T--,---C--C-----------HHHHHHH-H---C--,---4--1-----------1003002-2---3--,18,1,19,---e--d-----------CCCCCCC-d---d--,7,2,E:0;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,E:1;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,A:4;D:4;E:4;F:1;G:1;H:1;I:1;K:12;L:2;M:1;N:5;P:2;R:2;S:5;T:2;Y:1,A:19;C:7;D:13;E:13;F:13;G:9;H:7;I:15;K:8;L:28;M:10;N:8;P:6;Q:8;R:7;S:7;T:7;V:16;Y:6,G:0;H:0,G:0;H:1,C:5;G:3;H:23;T:17,C:15;E:13;G:12;H:143;T:24,18_1,E:1;F:1;I:1;K:1;L:3;N:1;P:1;Q:1;T:2;V:2,G:1;H:13,E:0;F:0;I:0;K:0;L:0;N:0;P:0;Q:0;T:0;V:0,G:0;H:0,---8--6-----------5656657-7---9--,ASN_106_A_COREBINDING;GLN_108_A_COREBINDING;GLU_265_A_COREBINDING;GLU_92_A_exosite;ILE_266_A_COREBINDING;LEU_105_A_COREBINDING;LEU_112_A_COREBINDING;LEU_262_A_COREBINDING;LYS_95_A_COREBINDING;PHE_100_A_COREBINDING;PRO_261_A_COREBINDING;THR_88_A_COREBINDING;THR_91_A_COREBINDING;VAL_109_A_COREBINDING;VAL_87_A_COREBINDING,LSLLQKLLLAT,0.533284918905834,0.196296296296296,1.07109943515997,---9--9-----------9999999-9---9--,LEU_1_B_e;SER_2_B_e;LEU_3_B_C;LEU_4_B_C;GLN_5_B_C;LYS_6_B_C;LEU_7_B_C;LEU_8_B_C;LEU_9_B_C;ALA_10_B_e;THR_11_B_e,"STRUCTURAL BASIS FOR ILOPROST AS A DUAL PPARALPHADELTA AGONIST"
3T03_B_D_18_1.pdb,3T03,22584573,2.10,P37231,PF00104,1.10.565.10,B,249,D,13,-------H---------KILHRLLQEGS---P-,-------C---------HHHHHHHHHCC---C-,-------2---------20012002302---4-,18,1,19,-------e---------dCCCCCCCDEE---E-,7,4,E:0;F:0;I:0;K:0;L:0;P:0;Q:0;T:0;V:0,E:0;F:0;I:0;K:1;L:0;P:0;Q:0;T:0;V:0,A:2;D:5;E:6;F:1;G:2;K:13;L:1;M:3;N:3;P:2;Q:4;R:2;S:3;T:2;Y:1,A:13;C:1;D:11;E:9;F:12;G:9;H:5;I:18;K:6;L:34;M:5;N:5;P:6;Q:8;R:6;S:10;T:8;V:12;Y:7,G:0;H:0,G:0;H:1,C:12;G:2;H:21;T:15,C:15;E:13;G:3;H:130;T:24,18_1,E:1;F:1;I:1;K:1;L:2;P:1;Q:2;T:1;V:2,G:1;H:11,E:1;F:0;I:0;K:0;L:0;P:0;Q:0;T:0;V:0,G:0;H:1,-------6---------65555445656---8-,GLN_71_B_COREBINDING;GLN_91_B_COREBINDING;GLU_245_B_COREBINDING;GLU_75_B_EXOSITE;ILE_246_B_COREBINDING;LEU_242_B_COREBINDING;LEU_95_B_COREBINDING;LYS_78_B_COREBINDING;LYS_96_B_exosite;PHE_83_B_COREBINDING;PRO_241_B_COREBINDING;THR_74_B_COREBINDING;VAL_70_B_COREBINDING;VAL_92_B_COREBINDING,LTERHKILHRLLQEGSPS,0.575861663849399,0.224899598393574,1.1071138152873,-------9---------99999999999---9-,HIS_1_D_e;LYS_2_D_e;ILE_3_D_C;LEU_4_D_C;HIS_5_D_C;ARG_6_D_C;LEU_7_D_C;LEU_8_D_C;GLN_9_D_C;GLU_10_D_E;GLY_11_D_E;SER_12_D_E;PRO_13_D_E,"CRYSTAL STRUCTURE OF PPAR GAMMA LIGAND BINDING DOMAIN IN COMPLEX WITH 2 A NOVEL PARTIAL AGONIST GQ16"
3VN2_A_C_18_1.pdb,3VN2,22357520,2.18,P37231,PF00104,1.10.565.10,A,261,C,11,R---------------HKILHRLLQE-------,C---------------CHHHHHHHCC-------,3---------------1200220023-------,18,1,19,e---------------ddCCCCCCCd-------,7,3,E:0;F:0;I:0;K:0;L:0;P:0;Q:0;T:0;V:0,E:0;F:0;I:0;K:1;L:0;P:0;Q:0;T:0;V:0,A:1;D:5;E:5;F:1;G:2;K:12;L:2;M:2;N:2;P:3;Q:3;S:4;T:4;Y:2,A:15;C:1;D:13;E:12;F:12;G:9;H:5;I:19;K:8;L:32;M:7;N:6;P:5;Q:10;R:8;S:12;T:7;V:13;Y:6,G:0;H:0,G:0;H:1,C:12;G:2;H:20;T:14,C:16;E:13;G:3;H:144;T:24,18_1,E:1;F:1;I:1;K:1;L:3;P:1;Q:2;T:1;V:1,G:1;H:11,E:0;F:0;I:0;K:0;L:0;P:0;Q:0;T:0;V:0,G:0;H:0,7---------------6655566678-------,GLN_79_A_COREBINDING;GLN_99_A_COREBINDING;GLU_256_A_COREBINDING;ILE_257_A_COREBINDING;LEU_103_A_COREBINDING;LEU_253_A_COREBINDING;LEU_96_A_COREBINDING;LYS_104_A_exosite;LYS_86_A_COREBINDING;PHE_91_A_COREBINDING;PRO_252_A_COREBINDING;THR_82_A_COREBINDING;VAL_100_A_COREBINDING,ERHKILHRLLQEGSPS,0.58105863030542,0.21455938697318,1.90568255488683,9---------------9999999999-------,ARG_1_C_e;HIS_2_C_e;LYS_3_C_e;ILE_4_C_C;LEU_5_C_C;HIS_6_C_C;ARG_7_C_C;LEU_8_C_C;LEU_9_C_C;GLN_10_C_C;GLU_11_C_e,"CRYSTAL STRUCTURE OF PPARGAMMA COMPLEXED WITH TELMISARTAN"
4NIE_B_C_18_1.pdb,4NIE,,2.01,P51449,PF00104,1.10.565.10,B,245,C,9,H-----K-----------ILHRLLQ--------,C-----H-----------HHHHHHC--------,1-----3-----------0013102--------,18,1,19,e-----d-----------CCCCCCC--------,7,2,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,A:3;D:1;E:6;H:6;I:1;K:2;L:1;P:2;Q:3;R:7;S:2;T:2;Y:2,A:14;C:8;D:4;E:15;F:12;G:9;H:7;I:9;K:8;L:29;M:5;N:6;P:3;Q:10;R:10;S:16;T:6;V:14;W:2;Y:7,G:0;H:0,G:0;H:0,C:4;G:4;H:22;T:8,B:1;C:20;E:9;G:14;H:129;T:21,18_1,E:1;F:1;I:1;K:2;L:3;M:1;P:1;Q:2;V:1,G:2;H:11,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,G:0;H:0,9-----9-----------9999999--------,GLN_83_B_COREBINDING;GLN_86_B_COREBINDING;GLU_241_B_COREBINDING;ILE_87_B_COREBINDING;LEU_238_B_COREBINDING;LEU_242_B_COREBINDING;LEU_90_B_COREBINDING;LYS_73_B_COREBINDING;LYS_91_B_COREBINDING;MET_79_B_COREBINDING;PHE_78_B_COREBINDING;PRO_237_B_COREBINDING;VAL_69_B_COREBINDING,KHKILHRLLQDS,0.375669415305114,0.983870967741936,0.514786363455754,9-----9-----------9999999--------,HIS_1_C_e;LYS_2_C_e;ILE_3_C_C;LEU_4_C_C;HIS_5_C_C;ARG_6_C_C;LEU_7_C_C;LEU_8_C_C;GLN_9_C_C,"CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORGAMMAT LIGAND 2 BINDING DOMAIN IN COMPLEX WITH SMALL MOLECULE LIGAND"
4S15_B_D_18_1.pdb,4S15,25651181,1.90,P35398,PF00104,1.10.565.10,B,250,D,9,--T---------------LLQLLLG-------H,--H---------------HHHHHHC-------C,--3---------------1012103-------2,18,1,19,--e---------------CCCCCCC-------e,7,1,E:0;F:0;I:0;K:0;L:0;M:0;Q:0;V:0,E:0;F:0;I:0;K:0;L:0;M:0;Q:0;V:0,A:3;C:1;D:6;E:8;F:1;G:1;H:3;K:7;L:3;M:1;N:1;P:2;Q:5;R:1;S:3;T:1;V:1;W:2,A:13;C:7;D:4;E:15;F:15;G:6;H:4;I:16;K:10;L:23;M:5;N:6;P:3;Q:12;R:9;S:12;T:9;V:12;W:1;Y:7,G:0;H:0,G:0;H:0,C:13;G:2;H:28;T:7,B:1;C:16;E:9;G:6;H:138;T:19,18_1,E:1;F:1;I:1;K:1;L:3;M:1;Q:2;V:1,G:2;H:9,E:0;F:0;I:0;K:0;L:0;M:0;Q:0;V:0,G:0;H:0,--7---------------4544556-------7,GLN_81_B_COREBINDING;GLN_84_B_COREBINDING;GLU_241_B_COREBINDING;ILE_85_B_COREBINDING;LEU_238_B_COREBINDING;LEU_242_B_COREBINDING;LEU_88_B_COREBINDING;LYS_71_B_COREBINDING;MET_77_B_COREBINDING;PHE_76_B_COREBINDING;VAL_67_B_COREBINDING,TLLQLLLGHKNE,0.326030634770185,0.516,2.84751786649355,--9---------------9999999-------9,THR_1_D_e;LEU_2_D_C;LEU_3_D_C;GLN_4_D_C;LEU_5_D_C;LEU_6_D_C;LEU_7_D_C;GLY_8_D_C;HIS_9_D_e,"CRYSTAL STRUCTURE OF THE ORPHAN NUCLEAR RECEPTOR RORALPHA LIGAND 2 BINDING DOMAIN IN COMPLEX WITH 4ALPHACABOXYL 4BETAMETHYL 3 ZYMOSTEROL 4ACD8"
4WLB_B_E_18_1.pdb,4WLB,25453817,1.70,P51449,PF00104,1.10.565.10,B,248,E,8,--S---------------LLKKLLD--------,--C---------------HHHHHHC--------,--2---------------1023103--------,18,1,19,--d---------------CCCCCCC--------,7,1,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,A:3;D:1;E:4;G:1;H:5;I:1;K:3;L:1;N:1;P:4;Q:2;R:6;S:5;T:1;Y:1,A:15;C:8;D:4;E:17;F:12;G:9;H:8;I:9;K:7;L:30;M:5;N:5;P:2;Q:11;R:11;S:14;T:6;V:14;W:2;Y:8,G:0;H:0,G:0;H:0,C:3;G:4;H:21;T:11,B:1;C:22;E:9;G:14;H:129;T:22,18_1,E:1;F:1;I:1;K:2;L:2;M:1;P:1;Q:2;V:1,G:2;H:10,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,G:0;H:0,--5---------------5675779--------,GLN_87_B_COREBINDING;GLN_90_B_COREBINDING;GLU_245_B_COREBINDING;ILE_91_B_COREBINDING;LEU_242_B_COREBINDING;LEU_94_B_COREBINDING;LYS_77_B_COREBINDING;LYS_95_B_COREBINDING;MET_83_B_COREBINDING;PHE_82_B_COREBINDING;PRO_241_B_COREBINDING;VAL_73_B_COREBINDING,SLLKKLLD,0.373941531013798,0.991935483870968,0.648519853204202,--9---------------9999999--------,SER_1_E_e;LEU_2_E_C;LEU_3_E_C;LYS_4_E_C;LYS_5_E_C;LEU_6_E_C;LEU_7_E_C;ASP_8_E_C,"CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PARTIAL INVERSE AGONIST 2 COMPOUND"
4WPF_D_E_18_1.pdb,4WPF,25815138,2.20,P51449,PF00104,1.10.565.10,D,246,E,11,-A---HK-----------ILHRLLQE-------,-C---CC-----------HHHHHHHC-------,-3---13-----------00120023-------,18,1,19,-e---ed-----------CCCCCCCd-------,7,3,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,E:0;F:0;I:0;K:1;L:0;M:0;P:0;Q:0;V:0,A:4;C:1;D:2;E:4;G:2;H:5;I:1;K:5;P:2;Q:4;R:8;S:2;T:2;Y:1,A:13;C:7;D:3;E:18;F:12;G:7;H:8;I:9;K:5;L:30;M:5;N:6;P:3;Q:9;R:9;S:16;T:6;V:14;W:2;Y:8,H:0;T:0,H:1;T:0,C:7;G:3;H:23;T:10,B:1;C:19;E:9;G:11;H:128;T:22,18_1,E:1;F:1;I:1;K:1;L:3;M:1;P:1;Q:2;V:1,H:10;T:2,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,H:0;T:0,-4---44-----------44444445-------,GLN_83_D_COREBINDING;GLN_86_D_COREBINDING;GLU_241_D_COREBINDING;ILE_87_D_COREBINDING;LEU_238_D_COREBINDING;LEU_242_D_COREBINDING;LEU_90_D_COREBINDING;LYS_240_D_exosite;LYS_73_D_COREBINDING;MET_79_D_COREBINDING;PHE_78_D_COREBINDING;PRO_237_D_COREBINDING;VAL_69_D_COREBINDING,AHKILHRLLQE,0.376757406686673,0.983870967741936,1.25618708797695,-9---99-----------99999999-------,ALA_1_E_e;HIS_2_E_e;LYS_3_E_e;ILE_4_E_C;LEU_5_E_C;HIS_6_E_C;ARG_7_E_C;LEU_8_E_C;LEU_9_E_C;GLN_10_E_C;GLU_11_E_e,"CRYSTAL STRUCTURE OF RORC IN COMPLEX WITH A PHENYL SULFONAMIDE AGONIST"
4XT9_A_B_18_1.pdb,4XT9,26277758,2.25,P51449,PF00104,1.10.565.10,A,243,B,8,--K---------------ILHRLLQ--------,--H---------------HHHHHHC--------,--4---------------0012002--------,18,1,19,--d---------------CCCCCCC--------,7,1,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,A:4;D:1;E:2;G:1;H:6;I:1;K:4;L:1;P:2;Q:4;R:7;S:5;T:1;Y:1,A:13;C:8;D:4;E:19;F:12;G:8;H:7;I:9;K:7;L:30;M:5;N:6;P:3;Q:9;R:10;S:13;T:6;V:14;W:2;Y:7,G:0;H:0,G:0;H:0,C:5;G:3;H:23;T:9,B:1;C:19;E:9;G:12;H:130;T:21,18_1,E:1;F:1;I:1;K:1;L:2;M:1;P:1;Q:2;V:1,G:2;H:9,E:0;F:0;I:0;K:0;L:0;M:0;P:0;Q:0;V:0,G:0;H:0,--9---------------9999999--------,GLN_82_A_COREBINDING;GLN_85_A_COREBINDING;GLU_240_A_COREBINDING;ILE_86_A_COREBINDING;LEU_237_A_COREBINDING;LEU_89_A_COREBINDING;LYS_72_A_COREBINDING;MET_78_A_COREBINDING;PHE_77_A_COREBINDING;PRO_236_A_COREBINDING;VAL_68_A_COREBINDING,KILHRLLQ,0.37607741867387,0.979838709677419,2.14217973102165,--9---------------9999999--------,LYS_1_B_e;ILE_2_B_C;LEU_3_B_C;HIS_4_B_C;ARG_5_B_C;LEU_6_B_C;LEU_7_B_C;GLN_8_B_C,"RORGAMMA 263509 COMPLEXED WITH GSK2435341A AND SRC2"
